JP2014530215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530215A5 JP2014530215A5 JP2014533618A JP2014533618A JP2014530215A5 JP 2014530215 A5 JP2014530215 A5 JP 2014530215A5 JP 2014533618 A JP2014533618 A JP 2014533618A JP 2014533618 A JP2014533618 A JP 2014533618A JP 2014530215 A5 JP2014530215 A5 JP 2014530215A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- seq
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 239000012634 fragment Substances 0.000 claims 47
- 239000003814 drug Substances 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 230000004614 tumor growth Effects 0.000 claims 4
- 102000048238 Neuregulin-1 Human genes 0.000 claims 3
- 108090000556 Neuregulin-1 Proteins 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010029098 Neoplasm skin Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541312P | 2011-09-30 | 2011-09-30 | |
| US61/541,312 | 2011-09-30 | ||
| US201161557460P | 2011-11-09 | 2011-11-09 | |
| US61/557,460 | 2011-11-09 | ||
| US201261614565P | 2012-03-23 | 2012-03-23 | |
| US61/614,565 | 2012-03-23 | ||
| PCT/US2012/056446 WO2013048883A2 (en) | 2011-09-30 | 2012-09-21 | Anti-erbb3 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017248591A Division JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530215A JP2014530215A (ja) | 2014-11-17 |
| JP2014530215A5 true JP2014530215A5 (OSRAM) | 2015-11-05 |
| JP6271432B2 JP6271432B2 (ja) | 2018-01-31 |
Family
ID=46970445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533618A Active JP6271432B2 (ja) | 2011-09-30 | 2012-09-21 | 抗ＥｒｂＢ３抗体およびその使用 |
| JP2017248591A Active JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017248591A Active JP6563472B2 (ja) | 2011-09-30 | 2017-12-26 | 抗ＥｒｂＢ３抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US8791244B2 (OSRAM) |
| EP (1) | EP2760893B1 (OSRAM) |
| JP (2) | JP6271432B2 (OSRAM) |
| KR (1) | KR20140069331A (OSRAM) |
| CN (1) | CN103917562B (OSRAM) |
| AR (1) | AR088171A1 (OSRAM) |
| AU (2) | AU2012316402B2 (OSRAM) |
| BR (1) | BR112014007382A2 (OSRAM) |
| CA (1) | CA2849508C (OSRAM) |
| CL (1) | CL2014000758A1 (OSRAM) |
| CO (1) | CO6940383A2 (OSRAM) |
| EA (2) | EA201791393A3 (OSRAM) |
| ES (1) | ES2694153T3 (OSRAM) |
| HK (1) | HK1200468A1 (OSRAM) |
| IL (2) | IL231318B (OSRAM) |
| IN (1) | IN2014CN03042A (OSRAM) |
| MX (1) | MX357391B (OSRAM) |
| PH (1) | PH12014500483A1 (OSRAM) |
| SG (1) | SG11201400150TA (OSRAM) |
| TW (2) | TW201329103A (OSRAM) |
| WO (1) | WO2013048883A2 (OSRAM) |
| ZA (1) | ZA201401424B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2516469T3 (en) | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| JP6271432B2 (ja) | 2011-09-30 | 2018-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥｒｂＢ３抗体およびその使用 |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| EA201500503A1 (ru) | 2012-11-08 | 2015-10-30 | Ф.Хоффманн-Ля Рош Аг | Анти-her3/her4 антигенсвязывающие белки, связывающиеся с бета-шпилькой her3 и бета-шпилькой her4 |
| CA2903882A1 (en) * | 2013-03-15 | 2014-09-18 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015058108A1 (en) * | 2013-10-17 | 2015-04-23 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| KR102127408B1 (ko) | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
| SG11201607109QA (en) * | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
| WO2015157634A1 (en) * | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| EP3791891A1 (en) * | 2014-07-17 | 2021-03-17 | Brian J. Czerniecki | Identification of immunogenic mhc class ii peptides for immune-based therapy |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| CA2959775A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| AU2016307943A1 (en) | 2015-08-14 | 2018-02-15 | Allergan, Inc. | Heavy chain only antibodies to PDGF |
| BR112018008068A2 (en) | 2015-10-23 | 2018-11-13 | Merus N.V. | binding molecules that inhibit cancer growth |
| KR101746152B1 (ko) * | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| JP6729926B2 (ja) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法 |
| KR20240074000A (ko) | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| CA3058343A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene |
| US12195551B2 (en) | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| HUE071182T2 (hu) | 2017-08-09 | 2025-08-28 | Merus Nv | EGFR és CMET kötõ antitestek |
| CN107860925B (zh) * | 2017-11-03 | 2019-07-12 | 合肥瀚科迈博生物技术有限公司 | 用于检测血清中HuA21抗体的ELISA检测试剂盒 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| WO2020059772A1 (ja) | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| WO2020072937A1 (en) * | 2018-10-04 | 2020-04-09 | The Trustees Of The University Of Pennsylvania | Antibodies against basement membrane zone adhesion proteins bp180 and bp230 |
| EP4637821A1 (en) * | 2022-12-23 | 2025-10-29 | Actinium Pharmaceuticals, Inc. | Her3 radioimmunotherapy for the treatment of solid cancers |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| HU221001B1 (hu) | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Egyláncú anti-EGFR Fv-k és anti-EGFR ellenanyagok |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
| US20010023241A1 (en) | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
| DE69920405T2 (de) | 1998-02-04 | 2006-01-05 | Genentech, Inc., South San Francisco | Verwendung des heregulins als epithelzellenwachstumsfaktor |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
| CZ200438A3 (cs) | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| WO2003012072A2 (en) | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| EP2263691B1 (en) | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| US7291293B2 (en) | 2003-02-28 | 2007-11-06 | Northwestern University | Vapor deposited electro-optic films self-assembled through hydrogen bonding |
| RS20150135A1 (sr) * | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US8323987B2 (en) | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| WO2007058823A2 (en) * | 2005-11-12 | 2007-05-24 | Eli Lilly And Company | Anti-egfr antibodies |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7498142B2 (en) | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| HRP20131113T1 (hr) * | 2007-02-16 | 2014-01-17 | Merrimack Pharmaceuticals, Inc. | Protutijela protiv erbb3 i njihova uporaba |
| EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| BRPI0917871A2 (pt) * | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| SG172393A1 (en) * | 2009-01-19 | 2011-07-28 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010085845A1 (en) | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
| CN102356092B (zh) * | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| EP2467164A2 (en) | 2009-08-21 | 2012-06-27 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
| EP2486052A4 (en) * | 2009-10-09 | 2013-05-01 | Merck Sharp & Dohme | GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| NO2719708T3 (OSRAM) | 2009-11-13 | 2018-03-24 | ||
| DK2516469T3 (en) * | 2009-12-22 | 2016-05-02 | Roche Glycart Ag | ANTI-HER3 antibodies and uses thereof |
| SG10201501562VA (en) * | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| JP2013522237A (ja) | 2010-03-11 | 2013-06-13 | メリマック ファーマシューティカルズ インコーポレーティッド | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| PL2606070T3 (pl) | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| JP6271432B2 (ja) | 2011-09-30 | 2018-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ＥｒｂＢ３抗体およびその使用 |
| TW201843172A (zh) | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
-
2012
- 2012-09-21 JP JP2014533618A patent/JP6271432B2/ja active Active
- 2012-09-21 AU AU2012316402A patent/AU2012316402B2/en active Active
- 2012-09-21 SG SG11201400150TA patent/SG11201400150TA/en unknown
- 2012-09-21 US US13/623,885 patent/US8791244B2/en active Active
- 2012-09-21 IN IN3042CHN2014 patent/IN2014CN03042A/en unknown
- 2012-09-21 KR KR1020147011692A patent/KR20140069331A/ko not_active Withdrawn
- 2012-09-21 CN CN201280045274.1A patent/CN103917562B/zh not_active Expired - Fee Related
- 2012-09-21 WO PCT/US2012/056446 patent/WO2013048883A2/en not_active Ceased
- 2012-09-21 EA EA201791393A patent/EA201791393A3/ru unknown
- 2012-09-21 MX MX2014003711A patent/MX357391B/es active IP Right Grant
- 2012-09-21 HK HK15100956.5A patent/HK1200468A1/xx unknown
- 2012-09-21 EP EP12768988.3A patent/EP2760893B1/en active Active
- 2012-09-21 ES ES12768988.3T patent/ES2694153T3/es active Active
- 2012-09-21 PH PH1/2014/500483A patent/PH12014500483A1/en unknown
- 2012-09-21 CA CA2849508A patent/CA2849508C/en active Active
- 2012-09-21 EA EA201490717A patent/EA028879B1/ru not_active IP Right Cessation
- 2012-09-21 BR BR112014007382A patent/BR112014007382A2/pt not_active IP Right Cessation
- 2012-09-27 AR ARP120103601A patent/AR088171A1/es unknown
- 2012-09-28 TW TW101135734A patent/TW201329103A/zh unknown
- 2012-09-28 TW TW106116405A patent/TW201809012A/zh unknown
-
2014
- 2014-02-25 ZA ZA2014/01424A patent/ZA201401424B/en unknown
- 2014-03-05 IL IL231318A patent/IL231318B/en not_active IP Right Cessation
- 2014-03-27 CL CL2014000758A patent/CL2014000758A1/es unknown
- 2014-04-30 CO CO14092568A patent/CO6940383A2/es active IP Right Grant
- 2014-06-18 US US14/308,527 patent/US9284380B2/en active Active
-
2016
- 2016-02-01 US US15/011,978 patent/US9827310B2/en active Active
-
2017
- 2017-04-12 IL IL251697A patent/IL251697A0/en unknown
- 2017-07-18 AU AU2017206185A patent/AU2017206185B2/en active Active
- 2017-10-25 US US15/793,756 patent/US10632194B2/en active Active
- 2017-12-26 JP JP2017248591A patent/JP6563472B2/ja active Active
-
2020
- 2020-04-14 US US16/848,752 patent/US11771762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530215A5 (OSRAM) | ||
| JP2018070648A5 (OSRAM) | ||
| JP2009545325A5 (OSRAM) | ||
| JP2015535828A5 (OSRAM) | ||
| JP2015517300A5 (OSRAM) | ||
| JP2013529183A5 (OSRAM) | ||
| JP2020528750A5 (OSRAM) | ||
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2014526898A5 (OSRAM) | ||
| JP2009505676A5 (OSRAM) | ||
| JP2017523786A5 (OSRAM) | ||
| JP2017149720A5 (OSRAM) | ||
| JP2019532619A5 (OSRAM) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2010535713A5 (OSRAM) | ||
| JP2014502955A5 (OSRAM) | ||
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2011046732A5 (OSRAM) | ||
| JP2014522843A5 (OSRAM) | ||
| JP2014205674A5 (OSRAM) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2016512223A5 (OSRAM) | ||
| JP2014511179A5 (OSRAM) | ||
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |